Hill W C
Sarasota Memorial Hospital, Florida 34239-3555, USA.
Clin Obstet Gynecol. 1995 Dec;38(4):725-45. doi: 10.1097/00003081-199538040-00008.
In this article, the author has reviewed available information on maternal, fetal, and neonatal risks and complications of tocolytic therapy. Because no ideal tocolytic agent exists, clinicians must be aware of the potential problems that can be encountered from initiating tocolysis. A variety of tocolytic agents may be effective in delaying preterm delivery. However, whether these agents reduce perinatal morbidity and mortality is debatable. This review emphasizes that serious complications occur from the use of these drugs including maternal, fetal, and neonatal death. Clinicians who use tocolysis, even oral terbutaline, must be aware of the significant side effects associated with these agents. Caution should be exercised not only in their initiation but also in their continuation. Additional research is needed and ongoing to limit the use of tocolytic agents and develop drugs with more efficacy, less risk, fewer complications, and more tolerable means of administration.
在本文中,作者回顾了有关宫缩抑制剂治疗的孕产妇、胎儿及新生儿风险和并发症的现有信息。由于不存在理想的宫缩抑制剂,临床医生必须意识到启动宫缩抑制可能会遇到的潜在问题。多种宫缩抑制剂可能有效延迟早产。然而,这些药物是否能降低围产期发病率和死亡率仍存在争议。本综述强调,使用这些药物会引发严重并发症,包括孕产妇、胎儿及新生儿死亡。使用宫缩抑制剂的临床医生,即使是口服特布他林,也必须意识到这些药物存在的显著副作用。不仅在开始使用时要谨慎,持续使用时也应如此。需要并正在进行更多研究,以限制宫缩抑制剂的使用,并研发出疗效更高、风险更低、并发症更少且给药方式更易耐受的药物。